Salley G Pels, MD

Assistant Professor of Pediatrics (Hematology / Oncology); Associate Director, Yale Hemostasis Center

Clinical Interests

  • Hematology
  • Medical Oncology
  • Pediatrics

Patient Care

Accepts new patients? Yes
Patient Type:
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Pediatric Hematology & Oncology Program

Pediatrics: Pediatric Hematology & Oncology

Yale Medical Group

Board Certifications

  • Pediatrics AB of Pediatrics (2009)

Clinical Trials

Conditions Study Title
Brain and Nervous System LGG-14C03 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Ill-Defined Sites American Thrombosis and Hemostasis Network (ATHN) Dataset Repository
Brain and Nervous System ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Non-Hodgkin's Lymphoma ANHL12P1 A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117.A Groupwide Phase II Study (Limited to US sites)
Hodgkin's Lymphoma AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in children and Adolescents A Groupwide Phase III Study (Limited to US and Canada sites) THIS
Hodgkin's Lymphoma AHOD1221 - A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
Soft Tissue ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) An Intergroup NCTN Phase II/III Study
Brain and Nervous System ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma A Groupwide Historically Controlled Phase III Study
Brain and Nervous System ACNS1221: A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Bones and Joints AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Other Hematopoietic Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children (the "Kids-DOTT" Trial)
Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)
Lymphoid Leukemia AALL1231 -- A Phase III Randomized Trial Investigating Bortezomib (NSC#681239; IND#58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL_ and T-Lymphoblastic Lymphoma (T-LLy) -- A Groupwide Phase III Study
Eye and Orbit ARET12P1 A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma: A Limited Institution Pilot Study
Unknown Sites My Life our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository
Other Respiratory and Intrathoracic Organs ALTE11C2: Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Preventionof Anthracycline-related Cardiomyopathy
Other Hematopoietic ACCL1034 Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Soft Tissue ANBL1221 A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#683864, IND#61010) or Chimeric 14.18 Antibody (ch 14.18) (NSC#623408, IND#4308) in Children with Refractory or Progressive Neuroblastoma
Leukemia, other ANHL1131 Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of Rituximab efficacy and safety in high risk patients
Unit Based Comparison of Non- versus Chlorhexidine-Impregnated Central Line Dressings

Edit this profile

Contact Info

Salley G Pels, MD
Patient Care Locations
Smilow Cancer Hospital at Yale - New Haven
35 Park Street

New Haven, CT 06511
5520 Park Avenue
Trumbull, CT 06611
Mailing Address
PO Box 208064
New Haven, CT 06520-8064